

1 **Phenotypical-, biochemical- and molecular-based techniques for**
2 **detection of metallo- β -lactamase NDM in *Acinetobacter baumannii***

3

4

5

6

Rémy A. Bonnin, Thierry Naas, Laurent Poirel, and Patrice Nordmann *

7

8

9

Service de Bactériologie-Virologie, INSERM U914 « Emerging Resistance to

10

Antibiotics », Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de

11

Médecine et Université Paris-Sud, K.-Bicêtre, France

12

13

14

15 Keywords: Carbapenemase, carbapenems, Hodge test, EDTA, β -lactamase, Gram

16 negatives

17 Running title: NDM-producer detection in *A. baumannii*

18

19 * Corresponding author. Mailing address: Service de Bactériologie-Virologie-Hygiène,

20 Hôpital de Bicêtre, 78 rue de Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France.

21 Phone: 33-1-45-21-36-32. Fax: 33-1-45-21-63-40

22 E-mail: nordmann.patrice@bct.aphp.fr

23 Seven NDM-positive *Acinetobacter baumannii* isolates of worldwide origin
24 were studied to evaluate the best technique for their identification. Detection of
25 carbapenemase producers based on the measurement of carbapenemase activity by
26 UV spectrophotometry (as for *A. baumannii* producing other types of
27 carbapenemase), or by the modified Hodge test, failed. Inhibition activity using
28 EDTA was a sensitive technique, but lacked of specificity as compared to molecular-
29 based techniques which remain the gold standard.

30 The emergence of the metallo- β -lactamase (MBL) named NDM-1 (New Dehli
31 metallo- β -lactamase) is one of the latest and most important resistance mechanisms
32 reported in Gram-negative rods (17). The *bla*_{NDM-1} gene identified initially in *Klebsiella*
33 *pneumoniae* and *Escherichia coli* mostly from India and Pakistan has been recently
34 identified extensively from other enterobacterial species worldwide (18). Besides spread
35 of NDM gene in *Enterobacteriaceae*, reports of NDM producers in *A. baumannii* are
36 increasingly identified worldwide (10-12).

37 Whereas detection of NDM producers in *Enterobacteriaceae* is easy (16), our
38 preliminary results indicated that detection of NDM-producing *A. baumannii* may be
39 much more complicated. Therefore, we evaluated several techniques for the detection of
40 NDM-producing *A. baumannii* clinical isolates.

41 A collection of seven NDM-positive *Acinetobacter baumannii* isolates of
42 worldwide origin was studied, to identify the best approach to detect the production of
43 NDM-type carbapenemases among clinical isolates. Another collection corresponding to
44 carbapenemase-producing but NDM-negative *A. baumannii* isolates of worldwide origin
45 was studied for comparison (Table 1). Those latter strains produced either Ambler class
46 B carbapenemases (IMP-4, VIM-4, or SIM-1), class D carbapenemases (OXA-23, OXA-
47 40, or OXA-58), or a class A carbapenemase (GES-14). Susceptibility testing was
48 performed by Etest (AB bioMérieux, Solna, Sweden) on Mueller-Hinton agar plates at
49 37°C, and results were classified according to the updated CLSI guidelines (3). The
50 CLSI breakpoints of *A. baumannii* for imipenem and meropenem were as follows:
51 susceptible (S) ≤ 4 $\mu\text{g/ml}$; resistant (R) ≥ 16 $\mu\text{g/ml}$ (3). The EUCAST breakpoints for
52 imipenem and meropenem were as follows: S ≤ 2 $\mu\text{g/ml}$; R ≥ 8 $\mu\text{g/ml}$. Whereas those for
53 doripenem were S ≤ 1 $\mu\text{g/ml}$; R ≥ 4 $\mu\text{g/ml}$ (6). All NDM-producing *A. baumannii* clinical

54 isolates were resistant to all β -lactams including all carbapenems according to CLSI and
55 EUCAST guidelines (Table 1).

56 The Etest MBL strip is one of the methods advocated for detection of MBLs based
57 on inhibition of the MBL activity by EDTA (16). This Etest method showed a good
58 sensitivity for the detection of MBL production. Susceptibility to imipenem was restored
59 in presence of EDTA confirming the significant impact of MBL as a source of
60 carbapenem resistance among MBL producers. However, several strains producing
61 OXA-23 or OXA-40 but being MBL negative gave false positive results (Table 1). This
62 showed that the intrinsic effect of EDTA on *A. baumannii* might interfere in the
63 specificity of this test.

64 Another technique was therefore evaluated to detect MBL production using the
65 same principle based on inhibition by EDTA. This technique consisted in two imipenem
66 disks with or without 10 μ l of EDTA 0.5 M (9). An increase of 10 mm of the inhibition
67 zone diameter in the presence of EDTA was considered as a positive result. An increase
68 between 5 and 10 mm was considered as doubtful and therefore requires further
69 investigations. This technique gave similar results as those obtained with Etest MBL
70 strips, with MBL producers being easily detected, except for an IMP-4-producing isolate
71 possessing low MICs of carbapenems (MIC of imipenem at 4 mg/l) (Fig. 1). However,
72 OXA-23 and OXA-40 producers gave some false-positive results as observed with Etest
73 MBL strips (Table 1, Fig. 1).

74 The Modified Hodge test (MHT) has been widely used screening of
75 carbapenemase activity because of the direct analysis of the carbapenemase activity. We
76 therefore evaluated MHT as previously described (14) at a turbidity of 0.5 McFarland,
77 using *E. coli* ATCC 25922 as indicator organism, *K. pneumoniae* BIC (producing the

78 carbapenemase OXA-48) as positive control, and *K. pneumoniae* COO (a non-
79 carbapenemase producing but carbapenem-resistant isolate) as negative control. It gave
80 negative results for all tested NDM-producing *A. baumannii* (Table 1). VIM-, IMP- and
81 some OXA-type producers gave weak synergistic images. This test was thus poorly
82 sensitive and specific for detecting the carbapenemase activity of any carbapenemase
83 producers.

84 Biochemical detection of NDM activity in *A. baumannii* was then analyzed. Ten
85 ml of overnight broth cultures of *A. baumannii* isolates was centrifuged at 5,000 x g
86 during 15 min and then sonicated in ice. Specific activities for carbapenems were
87 measured using UV spectrophotometry at a wavelength value of 297 nm for imipenem as
88 described (4). Detection of carbapenemase activity by UV spectrophotometry performed
89 with crude culture extracts of NDM producers did not give any significant positive
90 result. The standard mean of specific activities obtained for the NDM-producers was
91 evaluated at 5.7 mU/mg of proteins. This value was not significant as compared to the
92 value obtained with the reference strain *A. baumannii* AYE strain (8) that does not
93 possess any acquired carbapenemase gene and is susceptible to imipenem (2.6 mU/mg of
94 proteins which correspond to the baseline). Specific activities measured using other
95 carbapenem molecules gave similar results but lower level of carbapenemase activities
96 (Table 1). Similar low-level activities were observed for carbapenem-hydrolyzing class
97 D β -lactamases (CHDL) whereas high level of activity was observed for class B β -
98 lactamases of other types VIM, IMP, and SIM (Table 1). The latter results may be related
99 to either stronger promoter or/and plasmid location of those MBL genes.

100 Molecular-based techniques performed as previously described (16), using
101 primers NDM-For (5'-GGTGCATGCCCGGTGAAATC-3') and NDM-Rev (5'-

102 ATGCTGGCCTTGGGGAACG-3') for internal gene amplification (660-bp in-size
103 amplicon), and primers pre-NDM-for (5'-CACCTCATGTTTGAATTCGCC-3') and pre-
104 NDM-rev (5'-CTCTGTCACATCGAAATCGC-3') for amplification of the entire gene
105 sequence (984-bp in-size amplicon), are useful tools for identification of NDM producers
106 and the precise identification of the resistance determinant, respectively. In a single case,
107 as reported previously, two carbapenemase genes were identified that were *bla*_{OXA-23} and
108 *bla*_{NDM-1} (20). Using these PCR-based techniques, all NDM producers were detected.
109 Multiplex PCR for detecting several carbapenemase genes should be adapted to *A.*
110 *baumannii* since recently developed multiplex PCR schemes focused on detection of
111 carbapenemase genes only in *Enterobacteriaceae*. One of the limit of molecular-based
112 techniques however corresponds to a lack of detection of carbapenemase producers due
113 to unknown carbapenemase genes.

114 This work indicates that identification of NDM producers may be suspected by
115 comparing results of MIC of carbapenems with or without EDTA. Detection of
116 carbapenemase activity using either the modified Hodge test or UV spectrophotometry is
117 likely to fail to detect NDM producers in *A. baumannii* whereas this detection is efficient
118 for in *Enterobacteriaceae*. The discrepancy between *A. baumannii* and
119 *Enterobacteriaceae* could be explained by a weak level enzyme production in *A.*
120 *baumannii* likely related to the chromosomal location (a single copy) of the *bla*_{NDM} gene.
121 Considering that many microbiology laboratories do not possess the facilities for
122 molecular detection, carbapenem-resistant *A. baumannii* should be screened first using
123 EDTA-inhibition based techniques following by further PCR-based techniques in
124 reference laboratory.

125 These observations may have clinical implications for detection and therefore for

126 controlling the spread of NDM producers in *A. baumannii* which is at our opinion one of
127 the most difficult task considering the persistence of multidrug resistant *A. baumannii* in
128 many health care facilities.

129

130

Acknowledgments

131 This work was mostly funded by the INSERM (U914), France, and from the
132 European Community (TEMPOtest-QC, HEALTH-2009-241742).

133

134

References

- 135 1. **Bonnin, R. A., P. Nordmann, A. Potron, H. Lécuyer, J.-R. Zahar, and L. Poirel.**
136 2011. Carbapenem-hydrolyzing GES-type extended-spectrum β -lactamase in
137 *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **55**:349-354.
- 138 2. **Bonnin, R. A., L. Poirel, M. Licker, and P. Nordmann.** 2011. Genetic diversity
139 of carbapenem-hydrolysing β -lactamases in *Acinetobacter baumannii* from Romanian
140 hospitals. *Clin. Microbiol. Infect.* **17**:1524-1528.
- 141 3. **Clinical and Laboratory Standards Institute.** 2011. Performance standards for
142 antimicrobial susceptibility testing: 19th informational supplement. CLSI document
143 M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
- 144 4. **Carrër, A., L. Poirel, M. Yilmaz, O. A. Akan, C. Feriha, G. Cuzon, G. Matar,**
145 **P. Honderlick, and P. Nordmann.** 2010. Spread of OXA-48-encoding plasmid in
146 Turkey and beyond. *Antimicrob. Agents Chemother.* **54**:1369-1373.
- 147 5. **Chu, Y. W., M. Afzal-Shah, E. T. Houang, M. I. Palepou, D. J. Lyon, N.**
148 **Woodford, and D. M. Livermore.** 2001. IMP-4, a novel metallo- β -lactamase from
149 nosocomial *Acinetobacter* spp. collected in Hong Kong between 1994 and 1998.
150 *Antimicrob. Agents Chemother.* **45**:710-714.
- 151 6. **Leclercq, R., R. Cantón, D. F. J. Brown, C. G. Giske, P. Heisig, A. P.**
152 **MacGowan, J. W. Mouton, P. Nordmann, A. C. Rodloff, G. M. Rossolini, C.-J.**
153 **Soussy, M. Steinbakk, T. G. Winstanley, and G. Kahlmeter.** 2011. EUCAST Expert
154 Rules in Antimicrobial Susceptibility Testing. In press. DOI:10.1111/j.1469-
155 0691.2011.03703.x.
- 156 7. **Figueiredo, S., L. Poirel, A. Papa, V. Koulourida, and P. Nordmann.** 2008.
157 First identification of VIM-4 metallo- β -lactamase in *Acinetobacter* spp. *Clin. Microbiol.*

- 158 Infect. **14**:289-290.
- 159 8. **Fournier, P. E., D. Vallenet, V. Barbe, S. Audic, H. Ogata, L. Poirel, H. Richet,**
160 **C. Robert, S. Mangenot, C. Abergel, P. Nordmann, J. Weissenbach, D. Raoult, and**
161 **J. M. Claverie.** 2006. Comparative genomics of multidrug resistance in *Acinetobacter*
162 *baumannii*. PLoS Genet. **2**:e7.
- 163 9. **Franklin C., L. Liolios, and A. Y. Peleg.** 2006. Phenotypic detection of
164 carbapenem-susceptible metallo- β -lactamase-producing gram-negative bacilli in the
165 clinical laboratory. J. Clin. Microbiol. **44**:3139-3144.
- 166 10. **Göttig, S., G. Wilharm, E. Zander, T. A. Wichelhaus, S. Göttig, K. P. Hunfeld,**
167 **H. Seifert, W. Witte, and P. G. Higgins.** 2010. Global spread of New Delhi metallo- β -
168 lactamase 1. Lancet Infect. Dis. **10**:828-829.
- 169 11. **Kaase, M., P. Nordmann, T. A. Wichelhaus, S. G. Gatermann, R. A. Bonnin,**
170 **and L. Poirel.** 2011. NDM-2 carbapenemase in *Acinetobacter baumannii* from Egypt. J.
171 Antimicrob. Chemother. **66**:1260-1262.
- 172 12. **Karthikeyan, K., M. A. Thirunarayan, and P. Krishnan.** 2010. Coexistence of
173 *bla*_{OXA-23} with *bla*_{NDM-1} and *armA* in clinical isolates of *Acinetobacter baumannii* from
174 India. J. Antimicrob. Chemother. **65**:2253-2254.
- 175 13. **Kumarasamy, K. K., M. A. Toleman, T. R. Walsh, J. Bagaria, F. Butt, R.**
176 **Balakrishnan, U. Chaudhary, M. Doumith, C. G. Giske, S. Irfan, P. Krishnan, A. V.**
177 **Kumar, S. Maharjan, S. Mushtaq, T. Noorie, D. L. Paterson, A. Pearson, C. Perry,**
178 **R. Pike, B. Rao, U. Ray, J. B. Sarma, M. Sharma, E. Sheridan, M. A. Thirunarayan,**
179 **J. Turton, S. Upadhyay, M. Warner, W. Welfare, Livermore D. M., and N.**
180 **Woodford.** 2010. Emergence of a new antibiotic resistance mechanism in India,
181 Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect.

- 182 Dis. **10**:597-602.
- 183 14. **Lee, K., Y. S. Lim, D. Yong, J. H. Yum, and Y Chong.** 2003. Evaluation of the
184 Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-
185 beta-lactamase-producing isolates of *Pseudomonas* spp. and *Acinetobacter* spp. J. Clin.
186 Microbiol. **41**:4623-4629.
- 187 15. **Lee, K., J. H. Yum, D. Yong, H. M. Lee, H. D. Kim, J. D. Docquier, G. M.**
188 **Rossolini, and Y. Chong.** 2005. Novel acquired metallo- β -lactamase gene, *bla*_{SIM-1}, in a
189 class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. Antimicrob.
190 Agents Chemother. **49**:4485-4491.
- 191 16. **Nordmann, P., L. Poirel, A. Carrère, M. A. Toleman, and T. R. Walsh.** 2011.
192 How to detect NDM-1 producers. J. Clin. Microbiol. **49**:718-21.
- 193 17. **Nordmann, P., L. Poirel, T. R. Walsh, and D. M. Livermore.** 2011. The
194 emerging NDM carbapenemases. Trends Microbiol. **19**:588-95.
- 195 18. **Nordmann, P., T. Naas, and L. Poirel.** 2011. Global spread of carbapenemase-
196 producing *Enterobacteriaceae*. Emerg. Infect. Dis. **17**:1791-1798.
- 197 19. **Poirel, L., S. Marqué, C. Héritier, C. Segonds, G. Chabanon, and P.**
198 **Nordmann.** 2005. OXA-58, a novel class D beta-lactamase involved in resistance to
199 carbapenems in *Acinetobacter baumannii*. Antimicrob Agents Chemother. **49**:202-208.
- 200 20. **Poirel, L., R. A. Bonnin, A. Boulanger, J. Schrenzel, M. Kaase, and P.**
201 **Nordmann.** 2011. Tn125-related acquisition and expression of *bla*_{NDM-1}-like genes in
202 *Acinetobacter baumannii*. Antimicrob. Agents Chemother. In press.
- 203 21. **Yong D, M. A. Toleman, C. G. Giske, H. S. Cho, K. Sundman, K. Lee, and T.**
204 **R. Walsh.** 2009. Characterization of a new metallo- β -lactamase gene, *bla*_{NDM-1}, and a
205 novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella*

206 *pneumoniae* sequence type 14 from India. Antimicrob. Agents Chemother. **53**:5046-
207 5054.

208 Figure legend.

209 Comparison of the IPM-EDTA synergy test for carbapenemase-producing *A. baumannii*
210 clinical isolates. (A) Imipenem disk (10 μ g) alone. Lane 1, NDM-1-producing *A.*
211 *baumannii* (isolate SLO); lane 2, NDM-2-producing *A. baumannii* (isolate ML); lane 3,
212 IMP-4-producing *A. baumannii* (isolate IMP); lane 4, VIM-4-producing *A.*
213 genomospecies 16 (isolate A154); lane 5, OXA-23-producing *A. baumannii* (isolate
214 Acb2); lane 6, OXA-58-producing *A. baumannii* (isolate MAY). (B) imipenem disk
215 supplemented with 10 μ l of EDTA at 0.5 M. A significant increase of the inhibition zone
216 in the presence of EDTA was considered as positive.

Table 1. Results of MIC values with the Etest MBL, combined disk IPM/IPM+EDTA test, modified Hodge test, specific activities and PCR-technique for detection of carbapenemase producers in *A. baumannii*.

Isolates	Acquired Carbapenemase gene(s)	MIC ($\mu\text{g/ml}$)						Etest MBL	IPM/IPM+EDTA test (Diameter +/- EDTA) (mm)	Hodge test	Specific activity (mU/mg) ^a			PCR results ^c	References
		CTX	CAZ	IPM	IPM+ EDTA	MEM	DOR				IPM	MEM	ERT		
<i>A. baumannii</i> SLO	NDM-1	>256	>256	>32	1	>32	>32	+	+(6/25)	-	5.1	0.6	1.4	+	This study
<i>A. baumannii</i> All	NDM-1	>256	>256	>32	<1	>32	>32	+	+(6/24)	-	5.9	0.9	1.4	+	10
<i>A. baumannii</i> Ora-1	NDM-1	>256	>256	>32	<1	>32	>32	+	+(6/22)	-	6.4	0.9	1.1	+	This study
<i>A. baumannii</i> StN	NDM-1	>256	>256	>32	<1	>32	>32	+	+(6/23)	-	6.3	0.8	1.2	+	This study
<i>A. baumannii</i> Gen	NDM-1, OXA-23	>256	>256	>32	3	>32	>32	+	+(6/18)	-	7.2	1.1	1.5	+	20
<i>A. baumannii</i> ML	NDM-2	>256	>256	>32	<1	>32	>32	+	+(6/23)	-	4.7	0.9	1.3	+	11
<i>A. baumannii</i> 124	NDM-2	>256	>256	>32	<1	>32	>32	+	+(6/23)	-	4.5	0.7	1.3	+	This study
<i>A. baumannii</i> IMP	IMP-4	>256	>256	4	<1	8	4	+	+/(14/20)	-	718.1	95.6	65.2	-	5
<i>A. genomospecies</i> 16 A154	VIM-4	>256	>256	32	<1	32	32	+	+(8/25)	+	279.8	45.2	33.3	-	7
<i>A. baumannii</i> SIM	SIM-1	>256	>256	3	<1	4	3	-/+	+/(21/29)	+ ^b	58.3	12.6	23.2	-	15
<i>A. baumannii</i> 35	OXA-23	>256	>256	32	4	32	24	-/+	+/(9/17)	-	2.8	1.1	0.8	-	This study
<i>A. baumannii</i> Acb2	OXA-23	>256	>256	32	4	32	24	-/+	+/(11/20)	-	2.1	1.1	0.8	-	2
<i>A. baumannii</i> Acb13	OXA-23	>256	>256	24	4	24	16	-/+	+/(11/18)	-	1.9	1.2	0.9	-	2
<i>A. baumannii</i> LAH	OXA-40	>256	128	32	12	>32	32	-/+	+/(7/18)	+ ^b	2.1	0.5	0.5	-	This study
<i>A. baumannii</i> MUZ	OXA-40	>256	256	32	12	>32	32	-/+	+/(7/16)	+ ^b	1.6	0.6	0.4	-	This study
<i>A. baumannii</i> Acb19	OXA-58	>256	>256	4	2	4	4	-	-(14/18)	-	3.1	1.2	1.5	-	2
<i>A. baumannii</i> MAY	OXA-58	8	2	3	2	2	1	-	-(15/17)	-	2.9	1.1	0.6	-	This study
<i>A. baumannii</i> MAD	OXA-58	256	256	24	16	24	24	-	-(11/15)	+ ^b	3.0	1.2	0.6	-	19
<i>A. baumannii</i> AP	GES-14	>256	>256	24	8	16	8	-	-(11/17)	+ ^b	7.5	1.4	1.1	-	1

^a Standard deviations were within 10% of the means.^b Weakly positive.^c PCR were performed in standards conditions with NDM-For and NDM-Rev primers .

Fig. 1.

